5-Amino-1MQ
45,00 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Accelerated lipolysis and fat oxidation without thermogenic effects.
- Improved mitochondrial efficiency and ATP production.
- Supports insulin sensitivity and glucose homeostasis.
- Interest in body recomposition protocols in combination with GLP-1 agonists.
- Supports NAD+ levels relevant to cellular longevity.
Description
5-Amino-1MQ
Metabolism / Fat Loss
MECHANISM OF ACTION
It inhibits nicotinamide N-methyltransferase (NNMT), helping to prevent the degradation of NAD+ precursors. The intracellular increase in NAD+ promotes a cellular metabolism geared toward oxidative phosphorylation, helps reduce lipogenesis in adipocytes, and activates SIRT1/AMPK-related pathways.
KEY BENEFITS
- Accelerated lipolysis and fat oxidation without thermogenic effects.
- Improved mitochondrial efficiency and ATP production.
- Supports insulin sensitivity and glucose homeostasis.
- Interest in body recomposition protocols in combination with GLP-1 agonists.
- Supports NAD+ levels relevant to cellular longevity.
SIDE EFFECTS AND SAFETY
Generally well tolerated. Mild gastrointestinal discomfort has been reported at higher doses. During prolonged treatment cycles, it is recommended to monitor h
nd lipid profiles.
RESEARCH AND CLINICAL NOTES
Studies in mice show a 7–8% reduction in body weight compared with controls that did not undergo caloric restriction. NNMT inhibition has been associated
with a reduction in markers of adipogenesis in 3T3-L1 cell lines.
TARGET PROFILE:
Biohackers, metabolic optimization, and weight management programs combined with GLP-1.
Additional information
| Weight | ,26 kg |
|---|
Ingredients and Nutrition
Ingredient 1 - cucumber extract
Ingredient 2 - bilberry extract
Indications
1 capsule in the morning
You may also like…
Hot
Algal Oil Omega 3 EPA/DHA, 100 capsules
- Vegan source of Omega-3: Schizochytrium microalgae oil, a sustainable alternative to fish oil.
- Cardiovascular health: DHA and EPA help reduce triglycerides, improve circulation, and control blood pressure.
- Brain and cognitive wellness: Supports memory, concentration, and prevents cognitive decline.
- Eye health: DHA is an essential component of the retina, helping maintain optimal vision.
- Anti-inflammatory properties: Alleviates symptoms of arthritis and other chronic inflammatory diseases.
- Suitable for vegans: Free from gluten, lactose, and preservatives.
Related products
New
BPC 157
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Accelerated healing of tendons, ligaments, muscles, and connective tissue.
- Protection of the gastrointestinal mucosa and support for ulcer healing.
- Neuroprotection and peripheral nerve regeneration.
- Powerful anti-inflammatory action through the suppression of pro-inflammatory cytokines.
- Systemic cytoprotective effects on multiple organ systems.
- Benefits at SNC: Research on depression, PTSD, and addictive behavior.
New
GHK-Cu
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A significant increase in collagen synthesis and improved skin firmness.
- Accelerated healing and reduced scarring.
- Stimulation of the hair follicle and improvement in hair density.
- Systemic anti-aging effect through modulation of gene expression.
- Systemic antioxidant and anti-inflammatory action.
- Bone Regeneration and Nerve Repair in Research Models.
Ipamorelin
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A clean GH surge with no side effects associated with cortisol or prolactin.
- Increased lean muscle mass and fat loss.
- Improved sleep quality and recovery.
- Regulation of intestinal motility, with application in ileus.
- Ideal for long-term use due to its selectivity profile.
- Reference for use in combination with CJC-1295 without DAC.
New
PT-141
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved sexual desire in men and women.
- Improvement of erectile function via the central nervous system.
- Approved by the FDA for HSDD in premenopausal women as Vyleesi.
- Effective in patients who do not respond to PDE5 inhibitors.
- It can be used as needed, 45–90 minutes before the activity.
New
Retatrutide 10 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
Snap-8
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Non-invasive wrinkle reduction equivalent to botulinum toxin, though gentler and safer.
- Reduction in the depth of dynamic wrinkles on the forehead, crow's feet, and glabellar lines.
- Used in conjunction with Matrixyl and GHK-Cu in comprehensive anti-aging regimens.
- Active ingredient for cosmetic formulations or injectable administration.
- The preferred alternative for patients seeking options that do not involve botulinum toxin.
SS-31
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Restoration of mitochondrial function in aged and diseased tissues.
- Improved cardiac function in heart failure.
- Renal protection in ischemia-reperfusion injury.
- Reduction of neuroinflammation.
- Preservation of Muscle Fiber in Aging and Sarcopenia.
- FDA Breakthrough Therapy Designation for Barth Syndrome.
New
Thymosin Alpha-1
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Restoration of T-cell immunity in immunocompromised patients.
- Reduction of viral load in hepatitis B and C.
- Adjunctive use in HIV, cancer immunotherapy, and sepsis.
- Improving the immune response to vaccines in older adults.
- Anti-inflammatory action through immune balance and Th1/Th2 regulation.
- Adjunctive use in COVID-19, with significant evidence from China and Italy.
